BRNS Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (17 geg. 2024 @ 23:00):

Stats
Dzisiejszy wolumen	375.00
Średni wolumen	23 677.00
Kapitalizacja rynkowa	91.54M
EPS	$0 ( 2024-05-10 )
Następna data zysków	( $-0.500 ) 2024-08-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	0
ATR14	$0.0310 (1.32%)

Insider Trading

Date	Person	Action	Amount	type
2024-05-10	Dawes Karen A	Buy	19 516	Share Option (Right to Buy)
2024-05-10	Scheeren Joseph	Buy	19 516	Share Option (Right to Buy)
2024-05-10	Phillips Anne M.	Buy	19 516	Share Option (Right to Buy)
2024-05-10	Hammacher Alex	Buy	19 516	Share Option (Right to Buy)
2024-05-10	Morgon Pierre A.	Buy	19 516	Share Option (Right to Buy)

INSIDER POWER
100.00
Last 6 transactions
Buy: 117 096 \| Sell: 0

Barinthus Biotherapeutics Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Barinthus Biotherapeutics Finanse

Annual	2023
Przychody:	$805 108
Zysk brutto:	$802 000 (99.61 %)
EPS:	$-1.920

FY	2023
Przychody:	$805 108
Zysk brutto:	$802 000 (99.61 %)
EPS:	$-1.920

FY	2022
Przychody:	$44.70M
Zysk brutto:	$44.70M (100.00 %)
EPS:	$0.140

Financial Reports:

No articles found.

Barinthus Biotherapeutics Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Barinthus Biotherapeutics

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in developing novel T cell immunotherapeutics to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. It is advancing a pipeline of product candidates across a range of therapeutic areas, including VTP-300, an immunotherapeutic candidate designed as a potential component of a functional cure for chronic HBV infection; VTP-200, a non-surgical product candidate for persistent high-risk human papillomavirus (HPV); VTP-1000, an autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease; VTP-850, a second-generation immunotherapeutic candidate designed to treat recurrent prostate cancer; and VTP-1100, a preclinical cancer candidate designed to utilize the SNAP-CI platform to treat patients with HPV-related cancer. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Harwell, the United Kingdom.